Last reviewed · How we verify
Ribociclib (Dose #1) (ribociclib-dose-1)
At a glance
| Generic name | ribociclib-dose-1 |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 1 |
Approved indications
Common side effects
- Neutropenia
- Anaemia
- Leukopenia
- Neutrophil count decreased
- White blood cell count decreased
- Alanine aminotransferase increased
- Aspartate aminotransferase increased
- Electrocardiogram QT prolonged
- Gamma-glutamyltransferase increased
- COVID-19
- Arthralgia
- Constipation
Key clinical trials
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (PHASE1, PHASE2)
- A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection (EARLY_PHASE1)
- Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ribociclib (Dose #1) CI brief — competitive landscape report
- Ribociclib (Dose #1) updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI